# Lung cancer

1 posts.

- [Silevertinib heads for a Phase 3 trial built around lung cancer that has spread to the brain](https://healthcarenews.io/news/silevertinib-phase-3-trial-egfr-lung-cancer-brain.md) (2026-11-10): Black Diamond plans a silevertinib Phase 3 trial in 2027 for EGFR lung cancer with brain metastases, after an FDA meeting and new Phase 2 data.